News

Aerie Pharmaceuticals Announces Public Offering of Common Stock

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole bookrunner for the offering. Aerie intends t

Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见

米兰–(BUSINESS WIRE)–(美国商业资讯) — 生物制药公司Dompé今天宣布,EMA(欧洲药品署)人用药品委员会(CHMP)发布了一项肯定意见,建议签发Oxervate®(cenegermin 滴眼液)用于治疗中度或重度神经营养性角膜炎成人患者的上市许可。该病是一种罕见的致残性眼病,可导致失明。迄今,该病缺乏满意的治疗方法。鉴于该病相关的风险及缺乏有效治疗选择,CHMP通过加速评估完成了审批。加速评估始于2016年11月,本周以肯定意见收尾。 神经营养性角膜炎的起源与三叉神经(负责眼解剖和功能的神经之一)损害有关,该损害可导致角膜敏感性丧失。该病最严重时可导致溃疡、溶解和角膜穿孔,影响患者的视力2。 若获得EMA孤儿药品委员会(COMP)证实及欧盟核准,Oxervate®将是世界上首个获准用于该适应证的生物技术孤儿药。 该活性药物的名称是Cenegermin,是人类神经生长因子(NGF)的重组版本,发现者是诺贝尔奖获得者Rita Levi Montalcini。该蛋白质由人体天然产生,参与神经细胞的发育、维护和生存3。Oxervate®以滴眼液的形式施用于神经营养

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful primary efficacy results of the Company’s 90-day Phase 3 “Mercury 2” registration trial for its fixed-dose combination product candidate, Roclatan™. The results of Mercury 2 were consistent

Interview with Rupa Basu, BIOTRONIK’s Senior VP of Marketing, Corporate Accounts and Strategy

Millions of people experience heart rhythm disturbances in their lifetime. This has propelled cardiac electrophysiology to become one of the most innovative fields in medicine today. BIOTRONIK, a privately owned, global company with headquarters in Germany, is one of the leaders in the cardiac rhythm management space. Aside from its European r (Read more...)

Laser-Induced Graphene Showing Promise as Implant Material

Scientists from Rice University and Israel’s Ben-Gurion University of the Negev have identified that laser-induced graphene, a material designed on purpose to have imperfections, both prevents the buildup of organic materials on its surface and can be used to electrically kill bacteria that comes in contact with it. While typical graphen (Read more...)